• Medientyp: E-Artikel
  • Titel: Trastuzumab Treatment beyond Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss Breast Cancer Centers
  • Beteiligte: Huober, Jens; Baumann, Michael; Rochlitz, Christoph; Aebi, Stefan; Güth, Uwe; von Moos, Roger; Müller, Andreas; von Rohr, Lukas; Widmer, Isabelle; Thürlimann, Beat
  • Erschienen: S. Karger AG, 2011
  • Erschienen in: Oncology
  • Umfang: 160-166
  • Sprache: Englisch
  • DOI: 10.1159/000333396
  • ISSN: 0030-2414; 1423-0232
  • Schlagwörter: Cancer Research ; Oncology ; General Medicine
  • Zusammenfassung: <jats:p>&lt;i&gt;Background:&lt;/i&gt; Trastuzumab is an established treatment for HER2-positive breast cancer (BC). We analyzed Swiss patterns of care in patients with HER2-positive BC after disease progression on trastuzumab-containing therapy for metastatic BC (MBC). &lt;i&gt;Patients and Methods:&lt;/i&gt; A retrospective analysis was performed in six Swiss BC centers. Patients with HER2-positive MBC treated with at least one infusion of trastuzumab for advanced disease between January 2006 and December 2007 were identified. Treatment patterns in first and further lines were analyzed. &lt;i&gt;Results:&lt;/i&gt; All of the 72 identified patients received trastuzumab as their first palliative anti-HER2 therapy, either as monotherapy (n = 23) or in combination with chemotherapy (typically taxane or vinorelbine; n = 49). Median time to progression was 8.1, 8.0 and 7.9 months in the monotherapy, trastuzumab-taxane and trastuzumab-vinorelbine cohorts, respectively. After progression on first-line anti-HER2 therapy, trastuzumab was continued in 67 of 68 patients who received further therapy. One patient received second-line lapatinib plus capecitabine. The median duration of anti-HER2 therapy was 20 months. Patients received a median of 4 lines of anti-HER2 therapy. &lt;i&gt;Conclusions:&lt;/i&gt; Durable responses were achieved with repeated exposure to anti-HER2 therapy. In a selected patient population, trastuzumab monotherapy appears to be a reasonable first-line treatment option.</jats:p>
  • Beschreibung: <jats:p>&lt;i&gt;Background:&lt;/i&gt; Trastuzumab is an established treatment for HER2-positive breast cancer (BC). We analyzed Swiss patterns of care in patients with HER2-positive BC after disease progression on trastuzumab-containing therapy for metastatic BC (MBC). &lt;i&gt;Patients and Methods:&lt;/i&gt; A retrospective analysis was performed in six Swiss BC centers. Patients with HER2-positive MBC treated with at least one infusion of trastuzumab for advanced disease between January 2006 and December 2007 were identified. Treatment patterns in first and further lines were analyzed. &lt;i&gt;Results:&lt;/i&gt; All of the 72 identified patients received trastuzumab as their first palliative anti-HER2 therapy, either as monotherapy (n = 23) or in combination with chemotherapy (typically taxane or vinorelbine; n = 49). Median time to progression was 8.1, 8.0 and 7.9 months in the monotherapy, trastuzumab-taxane and trastuzumab-vinorelbine cohorts, respectively. After progression on first-line anti-HER2 therapy, trastuzumab was continued in 67 of 68 patients who received further therapy. One patient received second-line lapatinib plus capecitabine. The median duration of anti-HER2 therapy was 20 months. Patients received a median of 4 lines of anti-HER2 therapy. &lt;i&gt;Conclusions:&lt;/i&gt; Durable responses were achieved with repeated exposure to anti-HER2 therapy. In a selected patient population, trastuzumab monotherapy appears to be a reasonable first-line treatment option.</jats:p>
  • Anmerkungen: